211 related articles for article (PubMed ID: 29514108)
1. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population.
Pu XH; Ye Q; Yang J; Wu HY; Ding XW; Shi J; Mao L; Fan XS; Chen J; Qiu YD; Huang Q
Hum Pathol; 2018 Jun; 76():100-109. PubMed ID: 29514108
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
3. C-MET in intrahepatic cholangiocarcinoma: High-Frequency amplification predicts protein expression and a unique molecular subtype.
Pu XH; Yue S; Wu HY; Yang J; Fan XS; Fu Y; Ye Q; Chen J
Pathol Res Pract; 2020 Apr; 216(4):152857. PubMed ID: 32089411
[TBL] [Abstract][Full Text] [Related]
4. Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.
Pu X; Zhu L; Li F; Zheng J; Wu H; Fu Y; Chen J; Qi L
Pathol Res Pract; 2020 Sep; 216(9):153116. PubMed ID: 32825971
[TBL] [Abstract][Full Text] [Related]
5. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
[TBL] [Abstract][Full Text] [Related]
6. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
[TBL] [Abstract][Full Text] [Related]
9. Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Frequent pTERT/TP53 Mutations and Comprises 2 Subgroups Based on Epstein-Barr Virus Infection.
Tsai JH; Liau JY; Lee CH; Jeng YM
Am J Surg Pathol; 2021 Oct; 45(10):1409-1418. PubMed ID: 33859071
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
11. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.
Sarcognato S; Gringeri E; Fassan M; Di Giunta M; Maffeis V; Guzzardo V; Cillo U; Guido M
Virchows Arch; 2019 Jan; 474(1):29-37. PubMed ID: 30377796
[TBL] [Abstract][Full Text] [Related]
13. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
Mahipal A; Tella SH; Kommalapati A; Anaya D; Kim R
Cancer Treat Rev; 2019 Aug; 78():1-7. PubMed ID: 31255945
[TBL] [Abstract][Full Text] [Related]
15. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
Ahn S; Lee J; Hong M; Kim ST; Park SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Jung SH; Kang WK; Kim KM
Mod Pathol; 2016 Sep; 29(9):1095-103. PubMed ID: 27230412
[TBL] [Abstract][Full Text] [Related]
16. Gatekeeper Mutations and Intratumoral Heterogeneity in
Smyth EC; Babina IS; Turner NC
Cancer Discov; 2017 Mar; 7(3):248-249. PubMed ID: 28264865
[TBL] [Abstract][Full Text] [Related]
17. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
18. Polyclonal Secondary
Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
[TBL] [Abstract][Full Text] [Related]
19. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
[TBL] [Abstract][Full Text] [Related]
20. Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma.
Brackett DG; Neyaz A; Arora K; Masia R; Mattia A; Zukerberg L; Misdraji J; Goyal L; Zhu AX; Ferrone CR; Yilmaz OH; Deshpande V
J Clin Pathol; 2020 Jan; 73(1):23-29. PubMed ID: 31422372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]